Board of Directors

Topelia has in place a highly experienced group of professionals whose technical and managerial backgrounds are outlined below:

Prof Thomas Borody 

Research Director

Prof Borody is most famous for his ground-breaking work developing the triple therapy cure for peptic ulcers in 19871, which has saved hundreds of thousands of lives, and the Australian health system more than $10 billion in medical care and operations2. Professor Borody has more than 190 patents and applications, 3 FDA-approved drugs on the market, and more than 300 peer-reviewed papers published.

Read more

Dr David Fox 

MD and CEO

Dr David Fox has enjoyed guiding and growing biotech companies as a fund manager, management consultant, tech transfer officer, equities analyst and personal investor for almost 20 years at groups including MTPConnect, Shaw and Partners, and Oracle Investment Management. David gained experience on the buy and sell-side of the financial markets after gaining first class honours with majors in microbiology and pharmacology followed by a PhD in finance.

Read more

Graham Sorensen 


Graham brings over 30 years’ expertise, providing corporate and taxation advice across a range of industries. Graham was a partner in PricewaterhouseCoopers’ Taxation Services practice for 29 years, until September 2019. He is now a Director of his consultancy practice, GSPN Pty Ltd and has particular experience and expertise in advising clients in relation to financial services, fund investment and infrastructure transactions, including buy-side and sell-side transactions and Government privatisations.

Read more
Topelia Director, Vic Dawson

Ms Vic Dawson 


Vic Dawson has amassed an impressive array of expertise over the 13 years as Strategy Director for the Centre for Digestive Diseases (CDD), managing day-to-day operations. With financial acuity for business management, she governs a staff of 60 at this busy gastro-endoscopy Day Hospital with added responsibility of negotiating numerous contracts. Vic plays an active role in the CDD’s Research and Development, actively collaborating in multiple clinical research projects that are reported in numerous clinical abstracts and papers. In addition, Vic helms the HR department at CDD which she formalised upon her appointment as Strategy Director, ensuring the rights of both CDD and her staff. Furthermore, Vic launched Axent Medical Pty Ltd and serves as its Managing Director. Axent is a boutique research and development company dedicated to providing innovative and advanced medical technologies largely dealing with the microbiome. Vic also has a background in early childhood education and served as a law clerk for Centre for Digestive Diseases prior to her senior management positions.

Read more


1  Borody, T.J. (2016).  Development of novel therapies for gut dysbioses. Open Publications of UTS Scholars (OPUS). Identifier: Link to thesis:  2  Eslick, G.D., Tilden, D., Arora, N., Torres, M. & Clancy, R.L. (2020). Clinical and economic impact of “triple therapy” for Helicobacter pylori eradication on peptic ulcer disease in Australia. Helicobacter, 25(6).  Doi: 10.1111/hel.12751 Link to article: